A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
The aim of the trial is to assess the benefit of adding high precision radiation therapy to chemotherapy and surgery for the treatment of pancreatic cancer.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG) and NHMRC CTC
Accrual Target
120
Expected Date of Accrual
31 December 2024
Trial Chairperson
Dr Andrew Oar, Gold Coast University Hospital
Trial Contact
MASTERPLAN.study@sydney.edu.au
Clinical Trial Registration
Related Post
29 July, 2026
TROG to run breast cancer trial in Australia after gaining $2.86m grant
LATEST NEWS: 29 July 2026 TROG Cancer Research is
21 July, 2026
New TROG Scientific Committee Chair-Elect and members bring diverse experience
LATEST NEWS: 21 July 2026 The TROG Scientific Committee